|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Purdue Pharma LP |
|---|---|
| Information provided by: | Purdue Pharma LP |
| ClinicalTrials.gov Identifier: | NCT00315445 |
Purpose
The objective of this study is to assess the safety of the buprenorphine transdermal system (5, 10, and 20) in comparison to placebo transdermal system and immediate release oxycodone/ acetaminophen in subjects with chronic back pain. The double-blind treatment intervention duration is 84 days during which time supplemental analgesic medication (non-steroidal anti-inflammatory drugs) will be allowed for all subjects in addition to study drug.
| Condition | Intervention | Phase |
|---|---|---|
|
Back Pain |
Drug: Buprenorphine transdermal patch Drug: Placebo oxycodone/acetaminophen tablets Drug: OXY/APAP Drug: Placebo transdermal patch (TDS) |
Phase III |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | A Comparative Study of Buprenorphine TDS, Oxycodone/ Acetaminophen Tablets Qid and Placebo in Patients With Chronic Back Pain |
| Enrollment: | 134 |
| Study Start Date: | December 1997 |
| Study Completion Date: | May 1998 |
| Primary Completion Date: | May 1998 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Placebo Comparator: Placebo
Placebo oxycodone (OXY)/acetaminophen (APAP) tablets and placebo transdermal patch (TDS) 5, 10, or 20
|
Drug: Placebo oxycodone/acetaminophen tablets
Placebo oxycodone/acetaminophen tablets; 1, 2, or 3 tablets taken four times/day.
Drug: Placebo transdermal patch (TDS)
Placebo transdermal patch 5, 10, or 20 applied transdermally for 7-day wear
|
|
Active Comparator: OXY/APAP
5 mg oxycodone/325 mg acetaminophen tablets
|
Drug: OXY/APAP
5 mg oxycodone / 325 mg acetaminophen tablets; 1, 2, or 3 tablets taken four times/day.
|
|
Experimental: BTDS
Buprenorphine transdermal patch 5, 10, or 20 mcg/hour
|
Drug: Buprenorphine transdermal patch
Buprenorphine 5, 10, or 20 mcg/hour patch applied transdermally for 7-day wear.
Other Name: Butrans™
|
Buprenorphine is a synthetic opioid analgesic with over twenty-five years of international clinical experience indicating it to be safe and effective in a variety of therapeutic situations for the relief of moderate to severe pain.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Other protocol-specific exclusion/inclusion criteria may apply.
Contacts and Locations| United States, Alabama | |
| Rheumatology Associates of North Alabama | |
| Huntsville, Alabama, United States, 35801 | |
| United States, Arizona | |
| Phoenix Orthopedic Center, Ltd. | |
| Phoenix, Arizona, United States, 85023 | |
| Phoenix Center for Clinical Research | |
| Phoenix, Arizona, United States, 85015 | |
| United States, Florida | |
| Gainesville Clinical Research Center | |
| Gainesville, Florida, United States, 32605 | |
| SeaView Research | |
| Miami, Florida, United States, 33134 | |
| Park Place Therapeutic Center | |
| Plantation, Florida, United States, 33324 | |
| United States, Georgia | |
| Atlanta Research Center | |
| Decatur, Georgia, United States, 30033 | |
| United States, Missouri | |
| The Center for Pharmaceutical Research, P.C. | |
| Kansas City, Missouri, United States, 64114 | |
| United States, New Jersey | |
| New Jersey Research Foundation | |
| Linwood, New Jersey, United States, 08221 | |
| United States, North Carolina | |
| North Carolina Clinical Research, Inc. | |
| Raleigh, North Carolina, United States, 27607 | |
| United States, Texas | |
| Research Across America | |
| Dallas, Texas, United States, 75234 | |
| Metroplex Clinical Research Center | |
| Dallas, Texas, United States, 75235 | |
More Information
| Responsible Party: | Medical Director, Medical Research, Purdue Pharma L.P. |
| ClinicalTrials.gov Identifier: | NCT00315445 History of Changes |
| Other Study ID Numbers: | BP96-0604 |
| Study First Received: | April 17, 2006 |
| Results First Received: | May 17, 2011 |
| Last Updated: | August 3, 2011 |
| Health Authority: | United States: Food and Drug Administration |
|
chronic back pain opioid transdermal |
|
Back Pain Pain Neurologic Manifestations Nervous System Diseases Signs and Symptoms Acetaminophen Acetaminophen, hydrocodone drug combination Buprenorphine Oxycodone Antipyretics Physiological Effects of Drugs Pharmacologic Actions Analgesics, Non-Narcotic |
Analgesics Sensory System Agents Peripheral Nervous System Agents Central Nervous System Agents Therapeutic Uses Analgesics, Opioid Central Nervous System Depressants Narcotic Antagonists Narcotics Anti-Inflammatory Agents, Non-Steroidal Anti-Inflammatory Agents Antirheumatic Agents |